BREV-100 Advances to Preclinical Milestones
January 25, 2025
BioRevolution is dedicated to building, restoring, and preserving muscle mass and strength for longevity. Our lead program, BREV-100, targets the glycogen degradation pathway to harness the body’s central mechanism of building functional muscle, mimicking the adaptive signals of intense resistance training across multiple muscle wasting diseases, including Glycogen Storage Disorders, Muscular Dystrophies, GLP-1–associated muscle wasting, and Sarcopenia.
Muscle Drives Movement, Metabolism, and Vital Internal Functions. BioRevolution Develops Metabolic and Regenerative Therapies That Rebuild Strength Across Rare and Chronic Muscle Diseases.
Estimated Number of People Globally Experiencing Muscle Wasting Related Diseases
Skeletal Muscle Accounts for ~40% of Total Body Mass and Is a Key Regulator of Metabolism, Glucose Homeostasis, and Survival
Muscle loss is central to glycogen storage diseases such as Pompe and rare genetic neuromuscular diseases such as DMD, driving progressive and disabling weakness
Muscle loss is a debilitating feature of heart failure, chronic kidney disease (CKD), and type 2 diabetes, driven by inflammation, hormonal changes, and metabolic dysfunction
Corticosteroids and chemotherapy cause direct muscle loss, while GLP-1 therapies can indirectly lead to muscle loss via reduced appetite and caloric intake
Sarcopenia affects millions, with adults over 35 losing 1-2% of their muscle each year and it accelerates after 60 driving frailty, loss of mobility, and higher mortality
Skeletal Muscle System
Controls movement, posture, and metabolism. BioRevolution restores metabolic balance to maintain lifelong strength.
Respiratory & Diaphragm Muscles
Controls movement, posture, and metabolism. BioRevolution restores metabolic balance to maintain lifelong strength.
Lower Limb & Mobility Muscles
Leg muscles are essential for walking and balance. We target pathways that prevent age- and disease-related muscle loss.
Upper Limb Muscles
Shoulder and arm weakness limits daily tasks. Restoring energy use improves strength, mobility, and independence.
Core & Trunk Muscles
The core stabilizes posture and balance. Improving metabolic efficiency rebuilds functional movement and endurance.
Our initial focus is on Pompe disease where glycogen accumulation impairs muscle function leading to severe disability and premature death. Ultimately, we aim to expand to broader indications characterized by metabolic defects (e.g., autophagy block, glycolysis defects in DMD), impaired proteostasis and mitochondrial dysfunction (sarcopenia), and energy restriction with reduced anabolic signaling (GLP-1–associated muscle loss).
BREV-100 is a first-in-class oral small molecule designed to address Pompe disease by:
| Lead Program | Disease | Early Pre-Clinical | In-Vivo Efficacy | Phase 1 | Global Rights | Next Milestone | |
|---|---|---|---|---|---|---|---|
| Glycogen Storage Diseases | Other Glycosen Storage Diseases | Pompe Disease | IND-Enabling Studies, In-Vino Efficacy Studies & Supporting Preclinical package | ||||
BREV-100First-in-Class |
Muscular Dystrophies | IND-Enabling Studies, In-Vino Efficacy Studies & Supporting Preclinical package | |||||
| GLP-1 Induced Muscle Wasting in Obestiy | In-Vino Efficacy Studies to validate Development Candidate | ||||||
| Sarcopenia | In-Vino Efficacy Studies to validate Development Candidate |
BioRevolution is founded and led by a seasoned team united by a singular mission to transform muscle biology and extend healthy human life for millions living with rare and chronic diseases.
Co-Founder & Chief Executive Officer
Thomas Butler is the Co-Founder and CEO, responsible for the company’s vision, strategy, and overall leadership. He drives organizational growth, partnerships, and long-term execution across all business functions.
Oliver Saunders is the Co-Founder and Chief Scientific Officer, leading scientific innovation and research strategy. He oversees R&D efforts, ensuring scientific rigor and the successful translation of research into real-world applications.
Chief Business Officer
Thanaa Makdsi serves as Chief Business Officer, overseeing commercial strategy, business development, and market expansion. She bridges innovation with execution to drive sustainable revenue growth.
Head of INTELLECTUAL PROPERTY
Ravi Upasani leads the company’s intellectual property strategy, protecting innovation through patents, trademarks, and IP governance. He ensures alignment between legal protection and business objectives.